CRISPR-edited cell lines are a useful tool to validate your antibodies before you start an experiment. They ensure you are using high quality reagents, so you can be confident in your results. Here we explain how you can use our edited cell lines for validation, the challenges to be aware of and how we can help you overcome them.
Acute Myeloid Leukaemia (AML) is a group of blood cancer malignancies that originate from the uncontrolled proliferation of blast cells in the bone marrow and circulating blood1. AML is a relatively rare disorder - representing less than 1% of total cancer cases.
A major study has been undertaken to gain a better understanding of thousands of mutations in the BRCA1 gene - a key gene in breast and ovarian cancers.
The only self-delivering siRNA for difficult-to-transfect cells carries a functional guarantee.
CRISPR technology now allows genes and molecular pathways to be examined with greater definition. We look at how knockout cell lines, either together with gene rescue and replication of disease mutations or as an independent cell model, can be used to validate your research and extend your findings
See from a real example how Horizon's reference standards can be used to validate a new NGS assay technology.
Top ten recommendations to validate your NGS assay.
Revealing the role of E3 ubiquitin ligases in DNA damage repair. One of the diverse new uses for the HAP1 cell line, one that has begun to draw significant attention, is in the field of DNA damage repair. A recent paper from Minoru Takata's group highlights this important application of this relatively new tool.
Essential genes are defined as genes that are critical for the survival of an organism. These are considered to be genes that are absolutely required for the cell to grown, proliferate and survive. Deletion of an essential gene from a cell eventually leads to the death of this cell or a severe proliferation defect. As a consequence, it is impossible to generate cells with a knock-out or deletion of essential genes.
Cancer fusion genes are hybrid genes that produce abnormal proteins believed to catalyze further cancer growth and increase invasiveness. Here we highlight novel research using CRISPR gene editing to specifically target cancer fusion genes, which could offer many potential therapeutic applications.